Nonalcoholic steatohepatitis (NASH), characterized by liver steatosis, inflammation and injury, has emerged as one of major causes for end-stage liver disease like hepatocellular carcinoma. However, what drives its progression?
Aug 25, 2022
0
12
With the launch of a new clinical trial supported by the National Institutes of Health, researchers are working to determine whether treating children diagnosed with the most severe form of fatty liver disease with a drug ...
Jan 12, 2012
0
0
Scientists at the Arkansas Children's Nutrition Center, a U.S. Department of Agriculture Agricultural Research Service Human Nutrition Research Center at the University of Arkansas for Medical Sciences, led by Dr. Martin ...
Apr 24, 2013
0
0
New research found the genetic variant Patatin-like phospholipase domain containing protein-3 (PNPLA3) acting in conjunction with the glucokinase regulatory protein (GCKR) is associated with increased susceptibility to fatty ...
Mar 23, 2012
0
0
A therapeutic compound developed at Virginia Commonwealth University, which may have broad applicability in acute organ injuries and in several metabolic diseases such as nonalcoholic fatty liver disease and nonalcoholic ...
May 19, 2015
0
20
New research suggests that estrogen protects women with nonalcoholic steatohepatitis (NASH) from severe liver fibrosis. According to the study published online in Hepatology, a journal of the American Association for the ...
Oct 29, 2013
0
0
(HealthDay)—Mass spectrometry (MS)-based profiling combined with clinical variables can identify nonalcoholic steatohepatitis (NASH), according to a study published in the October issue of Clinical Gastroenterology and ...
Oct 6, 2016
0
0
The commonly used food additive monosodium glutamate (MSG) has been linked to obesity and disorders associated with the metabolic syndrome including progressive liver disease. A new study that identifies MSG as a critical ...
May 27, 2014
0
0
(HealthDay)—A novel non-elective inpatient hepatology rotation increases knowledge of chronic liver disease (CLD) among internal medicine (IM) residents, according to a study published online Aug. 10 in Hepatology.
Sep 6, 2016
0
0
